AuditLine › HHS OIG › Centers for Medicare and Medicaid Services
HHS OIG recommendation 21-A-09-107.04
To strengthen program safeguards for preventing and detecting improper payments for drug testing services and to address the three specific…
The recommendation, in the publisher's words
To strengthen program safeguards for preventing and detecting improper payments for drug testing services and to address the three specific weaknesses we identified in this report, we recommend that the Centers for Medicare & Medicaid Services work with its Medicare contractors to determine whether a postpayment medical review is necessary for laboratories that have been paid for excessive definitive drug tests (e.g., more than one test) in a 1-week period for the same beneficiary.
- Responsible agency
- Centers for Medicare and Medicaid Services
- Issued
- June 8, 2021
- Report
- Opportunities Exist for CMS and Its Medicare Contractors To Strengthen Program Safeguards To Prevent and Detect Improper Payments for Drug Testing Services (A-09-20-03017) · find it at HHS OIG
- Kind of report
- Audit
- Agency response
- Concur (as recorded by the publisher)
- Closed
- December 9, 2022 (publisher's date)
- Publisher topics
- Laboratories, Substance Abuse Disorder
“Open” and “closed” are the publisher's words. AuditLine repeats them with the date it read them. It does not check whether a recommendation was carried out, and a closed recommendation is not proof that a problem was fixed.
Dated history
- Issued by HHS OIG. (publisher's date)
- Closed, with status “Closed Implemented”. (publisher's date)
- First recorded by AuditLine. (start of AuditLine's own history for this record)
Dates marked "publisher's date" come from the publisher's file. AuditLine's own observations begin November 10, 2026 and are added each time the publisher's file changes.
Other recommendations from this report
4 more, of which 0 are open in the publisher's file.
- To strengthen program safeguards for preventing and detecting improper payments for drug testing services and to address the three specific weaknesses we identified in this report, we…HHS OIG 21-A-09-107.01 · issued Jun 8, 2021 · closed Oct 27, 2021Closed Unimplemented
- To strengthen program safeguards for preventing and detecting improper payments for drug testing services and to address the three specific weaknesses we identified in this report, we…HHS OIG 21-A-09-107.02 · issued Jun 8, 2021 · closed Oct 27, 2021Closed Unimplemented
- To strengthen program safeguards for preventing and detecting improper payments for drug testing services and to address the three specific weaknesses we identified in this report, we…HHS OIG 21-A-09-107.03 · issued Jun 8, 2021 · closed Oct 27, 2021Closed Unimplemented
- To strengthen program safeguards for preventing and detecting improper payments for drug testing services and to address the three specific weaknesses we identified in this report, we…HHS OIG 21-A-09-107.05 · issued Jun 8, 2021 · closed Dec 9, 2022Closed Implemented
Source
Open this report in HHS OIG's tracker This publisher's records (CSV)
Official export: https://oig.hhs.gov/recommendations/export-recs/. File read , 4,677 rows,
SHA-256 664fdfb3658ecb72…. HHS OIG's status, response, dates and potential-savings labels are the publisher's own claims.